Tagged Articles

attorneys 337 articles

Personal injury lawsuits target testosterone makers


A conference to review the progress of discovery efforts in a group of more than 1,340 lawsuits against manufacturers of testosterone treatments is scheduled for April 21, and the first case is expected to go trial in the fall of 2016. The lawsuits were consolidated in U.S. District Court in the Northern District of Illinois and target seven testosterone makers claiming the drugs caused heart attacks, strokes and other health problems. Testosterone treatments are prescription hormones that are designed to treat hypogonadism, a condition in which men do not produce enough testosterone due to injury or disease. Pharmaceutical companies have ... Read More

Defective metal hips once considered ‘best scientific solution’

metal on metal hip parts

Manufacturers of a metal-on-metal hip replacement system that injured tens of thousands of patients considered the defective metal hips to be “state-of-the-art” and “the best scientific solution available,” until adverse events showed the devices were failing miserably. Johnson & Johnson unit Depuy Orthopaedics introduced the ASR Acetabular hip implant in 2004. The device was considered revolutionary because unlike traditional hip implants, which are made of plastic or ceramic parts, the ASR was designed with all metal parts intended to be more durable and last longer than the 20 years typically given for traditional implants. Within five years, however, the Food and Drug Administration ... Read More

NHTSA to investigate company’s failure to recall Chinese-made tires

shredded tire BA istock

Federal safety regulators are investigating potentially defective Chinese-made tires imported to the U.S. and sold under different brand names by a single distributor after finding that the tires were recalled under one importer but not another. The National Highway Traffic Safety Administration (NHTSA) launched the probe after receiving a tip from a law firm litigating a personal-injury case involving the tires. Lawyers in that case wrote to NHTSA alleging that eight sizes of Hercules Radial A/T tires made for light cars and trucks by Shandong Yongsheng Rubber Co. Ltd. remained on the road when virtually identical tires made by the ... Read More

Ford must submit source code in sudden unintended acceleration case


Ford Motor Co. must turn over portions of its proprietary source code to plaintiffs suing the auto manufacturer over alleged defects in the electronic throttle control (ETC) system of certain vehicles, causing them to accelerate suddenly and unexpectedly, a West Virginia federal judge ordered Friday. Attorneys representing plaintiffs in a proposed class action argued that the source code is instrumental to understanding an alleged glitch that can cause sudden unintended acceleration in vehicles made from 2002 to 2010. They likened the problem to nearly identical claims made against Toyota for sudden unintended acceleration. Electronic source code played a key role ... Read More

Rhode Island man sues Xarelto over bleeding risks


A Rhode Island man is suing the makers of the blood thinner Xarelto claiming the manufacturers misled the public by marketing the drug as safe while not revealing the odds of serious bleeding side effects associated with the drug. The lawsuit also claims that no antidote is available to reverse the blood thinning effects once uncontrolled bleeding occurs. Daniel Hernandez filed his lawsuit against Johnson & Johnson unit Janssen Pharmaceuticals and Bayer Healthcare AG, and several of their subsidiaries that manufacture and distribute Xarelto. The blood thinner, which was initially approved in 2011, is used to prevent strokes in some ... Read More

Takeda dismisses possibility of billion-dollar Actos bladder cancer settlement

Actos (pioglitazone) Type 2 diabetes medication

News that Takeda Pharmaceutical Co. plans to pay $2.2 billion to settle about 8,000 federal and state lawsuits over bladder cancer risks with its type 2 diabetes drug Actos are merely “marketplace rumors,” according to a statement the drug company provided for Law360. “Takeda has confidence in Actos as a treatment option and will continue to vigorously defend the company in these types of cases,” the statement read. “It would be inappropriate to comment further on marketplace rumors.” The statement followed a Bloomberg report that the drug company had offered to pay more than $2.2 billion to resolve Actos bladder ... Read More

FDA releases guidelines for abuse-deterrent versions of opioids


Eighteen months after the Food and Drug Administration (FDA) approved Zogenix Inc.’s powerful opioid painkiller Zyhydro despite abuse concerns from consumer groups and lawmakers, the agency has finalized its guidance urging drug makers to devise abuse-deterrent versions of opioids as they move forward. The new formulations of opioids – some of which have already hit the market – are manufactured in a way that prevents them from being crushed and injected or snorted, which many of these painkillers are for a stronger, more intense high, contributing to the country’s prescription drug abuse epidemic. The FDA guidance informs drug makers of ... Read More

Bayer banks on sales of blood thinner Xarelto


Bayer announced it plans to increase sales for its main Healthcare division by 6 percent on average through 2017 to more than $26.7 billion by hanging its hat on new drugs, such as the blood thinner Xarelto. The company says rising sales of these newer drugs have helped offset declines of its birth control pill and multiple sclerosis treatment in the face of competition. Bayer teamed up with Johnson & Johnson subsidiary Janssen Pharmaceuticals to produce Xarelto, which became the second drug in a new class of blood thinners called Xa inhibitors. The anticoagulant is used to prevent or treat blood ... Read More

Melanoma drug proves superior in clinical trials


Merck & Co.’s cancer drug Keytruda (pembrolizumab) was superior in treating patients of advanced melanoma in phase III clinical trials compared to Bristol-Myers Squibb Co.’s Yervoy (ipilimumab). Keytruda is in a class of cancer drugs known as PD-1 inhibitors. It is currently approved for the treatment of unresectable or metastatic melanoma, and in patients whose disease has progressed after the use of the standard treatment, Yervoy. The positive results of the latest trial of Keytruda is good news for the large number of patients worldwide with skin cancer. Melanoma is the deadliest form of skin cancer because it can be ... Read More

Lawsuit claims arsenic in wines is dangerously high

wine - arsenic

A class action lawsuit filed in behalf of California consumers claims that California wineries are producing wine contaminated with dangerously high levels of arsenic and failing to warn consumers about the potential risks of arsenic exposure. The lawsuit targets 28 wineries including Franzia, Sutter Home, Wine Cube, Cupcake, Beringer and Vendage, and involve mostly inexpensive white or blush varieties such as moscato, pinot grigio, and sauvignon blanc. Plaintiffs attorneys say 1,306 different types of wine were tested by BeverageGrades of Denver, and 83 showed dangerously elevated levels of inorganic arsenic in wines. The results were confirmed by two other labs. ... Read More